Thilo Schroeder bought $60.0M of Revolution Medicines (RVMD)
Executed Dec 5 2024, disclosed Dec 9 2024, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Dec 9 2024), the stock returned -7.1% (delay-adjusted); from the execution session (Dec 5 2024), -9.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Thilo Schroeder (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Revolution Medicines, Inc. (RVMD). Across 1 priced purchase filing, the average 21-session return was -9.3% from execution and -7.1% from disclosure (delay-adjusted; derived). The largest single filing was $60.0M of RVMD (1,304,347 sh across 2 lots, as filed), executed Dec 5 2024.
Healthcare · Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→